The North America human leukocyte antigen (HLA) testing market is expected to grow from US$ 324.49 million in 2022 to US$ 504.72 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.
Human leukocyte antigens (HLAs) are specialized proteins present on all cell surfaces of the human body except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues. The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice area. Governments of various countries are taking initiatives to spread awareness about the need for organ donation and the benefits of organ transplantation in certain treatment procedures. For instance, the Organ Procurement and Transplantation Network (OPTN) has implemented a few strategies to improve the number of organ transplantation procedures in the US. These strategies focus on increasing the number of organ and tissue transplants among patients with end-stage organ disease, altering the current organ distribution, and modifying the organ transplantation waitlist by redistributing the existing organ soppy. Furthermore, the OPTN has used out-of-box strategies to improve organ transplantation. These innovative strategies include the optimized use of organs obtained from deceased patients [e.g., donation after cardiac death (DCD) or brain-dead donors], reducing discards of organs, promoting living donation, and improving the rate of potential organ donation authorization. Thus, the growing demand for organ transplantation leads to the requirement of a more substantial number of HLA testing kits and consumables, which drives the HLA testing market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the north america human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.
Human leukocyte antigens (HLAs) are specialized proteins present on all cell surfaces of the human body except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues. The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice area. Governments of various countries are taking initiatives to spread awareness about the need for organ donation and the benefits of organ transplantation in certain treatment procedures. For instance, the Organ Procurement and Transplantation Network (OPTN) has implemented a few strategies to improve the number of organ transplantation procedures in the US. These strategies focus on increasing the number of organ and tissue transplants among patients with end-stage organ disease, altering the current organ distribution, and modifying the organ transplantation waitlist by redistributing the existing organ soppy. Furthermore, the OPTN has used out-of-box strategies to improve organ transplantation. These innovative strategies include the optimized use of organs obtained from deceased patients [e.g., donation after cardiac death (DCD) or brain-dead donors], reducing discards of organs, promoting living donation, and improving the rate of potential organ donation authorization. Thus, the growing demand for organ transplantation leads to the requirement of a more substantial number of HLA testing kits and consumables, which drives the HLA testing market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the north america human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.
North America Human Leukocyte Antigen (HLA) Testing Market Segmentation
The North America human leukocyte antigen (HLA) testing market is segmented into product & services, technology, end user, and country.- Based on product & services, the market is segmented into reagents & consumables, instruments, and software & services. In terms of technology, the North America human leukocyte antigen (HLA) testing market is divided into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment is sub segmented into PCR-based molecular assays, sequencing-based molecular assays, and others.
- Based on end user, the market is divided into independent reference laboratories, hospital and transplant centers, and others.
- Based on country, the North America human leukocyte antigen (HLA) testing market is segmented into the US, Mexico, and Canada.
North America Human Leukocyte Antigen (HLA) Testing Market - Companies Mentioned
THERMO FISHER SCIENTIFIC INC.; CareDx; QIAGEN; Illumina, Inc.; Bio-Rad Laboratories, Inc.; TBG Diagnostics Limited; F. HOFFMANN-LA ROCHE LTD.; Takara Bio Inc.; Luminex Corporation; Omixon Inc.; The Sequencing Center; HistoGenetics LLC; CD Genomics; Quintara Biosciences; and CREATIVE BIOLABS, INC. are among the major companies operating in the North America human leukocyte antigen (HLA) testing market.Table of Contents
1. Introduction
3. Research Methodology
4. North America Human Leukocyte Antigen (HLA) Testing Market - Market Landscape
5. North America Human Leukocyte Antigen (HLA) Testing Market - Key Market Dynamics
6. North America Human Leukocyte Antigen (HLA) Testing Market - Analysis
7. North America Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028 - by Product and Services
8. North America Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by Technology
9. North America Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by End User
10. North America Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by Country
11. North America Human Leukocyte Antigen (HLA) Testing Market - Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- THERMO FISHER SCIENTIFIC INC.
- CareDx
- QIAGEN
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- TBG Diagnostics Limited
- F. HOFFMANN-LA ROCHE LTD.
- Takara Bio Inc.
- Luminex Corporation
- Omixon Inc.
- The Sequencing Center
- HistoGenetics LLC
- CD Genomics
- Quintara Biosciences
- CREATIVE BIOLABS, INC.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 172 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 324.49 Million |
| Forecasted Market Value ( USD | $ 504.72 Million |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | North America |
